Ashish Pradhan, MD, Executive Director and Disease Area Lead for MS and NMOSD at Genentech, discusses the 4-year data examining the efficacy and safety of satralizumab to treat neuromyelitis optica spectrum disorder (NMOSD). This data was recently presented at the ECTRIMS 2021 Annual Meeting.
NMOSD is a rare central nervous disorder that primarily affects the spinal cord and optic nerves. Symptoms of NMOSD may include blindness in one or both eyes, weakness or paralysis of arms or legs, spasming, loss of sensation, uncontrollable vomiting and hiccups, and bladder/bowel problems due to spinal cord damage. Satralizumab was approved for the treatment of AQP4 antibody-positive NMOSD patients in August 2020.
As Dr. Pradham explains, 4-year data from the SAkuraStar and SAkuraSky open-label extension studies demonstrates that the efficacy of satralizumab observed in the pivotal trials is sustained with 73% (SAkuraStar) and 71% (SAkuraSky) of NMOSD patients remaining relapse-free after 4 years of treatment. Similarly, safety data from these open-label extension studies show that the favorable safety profile of satralizumab is sustained after 4 or more years.
To learn more about NMOSD and other rare neurological disorders, visit checkrare.com/diseases/neurology
References
Chugai Pharmaceutical Co [news release]. New Four-year Data Show Sustained Relapse Reduction by Chugai’s Enspryng in People With Neuromyelitis Optica Spectrum Disorder (NMOSD). October 14, 2021. https://www.businesswire.com/news/home/20211014005415/en/New-Four-year-Data-Show-Sustained-Relapse-Reduction-by-Chugai%E2%80%99s-Enspryng-in-People-With-Neuromyelitis-Optica-Spectrum-Disorder-NMOSD
U.S. Food and Drug Administration [news release]. New Four-year Data Show Sustained Relapse Reduction by Chugai’s Enspryng in People With Neuromyelitis Optica Spectrum Disorder (NMOSD). August 17, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-rare-disease-affecting-optic-nerves-spinal-cord